| Literature DB >> 36012216 |
Eun Gyung Park1,2, Hongseok Ha3, Du Hyeong Lee1,2, Woo Ryung Kim1,2, Yun Ju Lee1,2, Woo Hyeon Bae1,2, Heui-Soo Kim2,4.
Abstract
It is estimated that up to 80% of the human genome is transcribed into RNA molecules but less than 2% of the genome encodes the proteins, and the rest of the RNA transcripts that are not translated into protein are called non-coding RNAs (ncRNAs). Many studies have revealed that ncRNAs have biochemical activities as epigenetic regulators at the post-transcriptional level. Growing evidence has demonstrated that transposable elements (TEs) contribute to a large percentage of ncRNAs' transcription. The TEs inserted into certain parts of the genome can act as alternative promoters, enhancers, and insulators, and the accumulation of TEs increases genetic diversity in the human genome. The TEs can also generate microRNAs, so-called miRNA-derived from transposable elements (MDTEs), and are also implicated in disease progression, such as infectious diseases and cancer. Here, we analyzed the origin of ncRNAs and reviewed the published literature on MDTEs related to disease progression.Entities:
Keywords: MDTE; disease; long non-coding RNA; non-coding RNA; transposable element
Mesh:
Substances:
Year: 2022 PMID: 36012216 PMCID: PMC9409130 DOI: 10.3390/ijms23168950
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Figure 1Percentage and composition of lncRNA transcripts overlapping TE sequences. (A) The percentage of TE subclasses produced by each chromosome; (B) The number of TE superfamilies overlapping with lncRNA transcripts from each TE subclasses: LTR, SINE, LINE, and DNA transposon.
Figure 2The schematic diagram of miRNA biogenesis via three independent pathways. TE, transposable element; m7G, 7-methylguanosine; DGCR8, DiGeorge syndrome critical region 8; TRBP, transactivation response element RNA-binding protein; RISC, RNA-Induced Silencing Complex; AGO, Argonaute.
Figure 3Percentage and composition of MDTEs. (A) The proportion of MDTEs in total miRNA and the distribution of TE subclasses from which miRNAs are derived; (B) The number of TE superfamilies that generate miRNAs from each TE subclasses, DNA transposon, LINE, SINE, and LTR.
Figure 4Chromosome ideogram shows the MDTEs in relation to (A) infectious diseases or (B) cancers. Each diagram indicates the chromosomal location of these MDTEs.
MDTEs in relation to pathogen-associated diseases.
| miRNA | Subclass | Superfamily | Subfamily | Disease | Dysregulation | Ref. |
|---|---|---|---|---|---|---|
| hsa-mir-1246 | LTR | ERVL-MaLR | MLT1M | Plasmodium Falciparum Malaria | upregulated | [ |
| hsa-mir-130a | LINE | RTE-BovB | MamRTE1 | Hepatitis C Virus Infection | upregulated | [ |
| hsa-mir-151a-3p | LINE | L2 | L2c | Chronic Hepatitis B | downregulated | [ |
| Helicobacter pylori Infection | upregulated | [ | ||||
| hsa-mir-28-3p | LINE | L2 | L2c | Helicobacter pylori Infection | upregulated | [ |
| hsa-mir-3909 | LINE | L2 | L2c | Rheumatic Heart Diseases | downregulated | [ |
| hsa-mir-3135b | SINE | Alu | FRAM | Plasmodium Falciparum Malaria | upregulated | [ |
| hsa-mir-345-5p | SINE | MIR | MIRc | Respiratory Syncytial Virus Pneumonia | downregulated | [ |
| hsa-mir-378a-3p | SINE | MIR | MIRc | Hepatitis C Virus Infection | upregulated | [ |
MDTEs in relation to human cancers.
| miRNA | Subclass | Superfamily | Subfamily | Target Gene | Disease | Ref. |
|---|---|---|---|---|---|---|
| hsa-mir-1202 | LTR | ERV1 | MER52A | CDK14 | Hepatocellular cancer | [ |
| hsa-mir-646 | LTR | ERVL | LTR67B | FOXK1 | Gastric cancer | [ |
| hsa-mir-1271-5p | LINE | L2 | L2a | DIXDC1 | Prostate cancer | [ |
| Foxk2 | Non-small-cell lung cancer | [ | ||||
| hsa-mir-130a-3p | LINE | RTE-BovB | MamRTE1 | FOSL1 | Breast cancer | [ |
| RAB5B | [ | |||||
| hsa-mir-374b-5p | LINE | L2 | L2c | AKT1 | Colon cancer | [ |
| JAM2 | Cervical cancer | [ | ||||
| ZEB2 | Bladder cancer | [ | ||||
| hsa-mir-421 | LINE | L2 | L2c | PDCD4 | Breast cancer | [ |
| hsa-mir-577 | LINE | L2 | L2a | WNT2B | Non-small-cell lung cancer | [ |
| hsa-mir-582-5p | LINE | CR1 | L3 | AKT3 | Endometrial cancer | [ |
| hsa-mir-608 | LINE | L2 | L2 | BRD4 | Hepatocellular cancer | [ |
| MIF | Lung cancer | [ | ||||
| hsa-mir-23c | SINE | MIR | MIRb | ERBB2IP | Hepatocellular cancer | [ |
| hsa-mir-330-3p | SINE | MIR | MIRb | CCBE1 | Breast cancer | [ |
| hsa-mir-345-5p | SINE | MIR | MIRc | AKT2 | Acute myelogenous leukemia | [ |
| hsa-mir-3908 | SINE | Alu | AluSx | AdipoR1 | Breast cancer | [ |
| hsa-mir-4317 | SINE | MIR | MIR | FGF9, CCND2 | Non-small-cell lung cancer | [ |
| hsa-mir-575 | SINE | MIR | MIR | ST7L | Hepatocellular cancer | [ |
| hsa-mir-612 | SINE | MIR | MIR1_Amn | ME1 | Bladder cancer | [ |
| hsa-mir-224-3p | DNA | DNA | MER135 | ST3GalIV | Renal Cell cancer | [ |
| hsa-mir-224-5p | RASSF8 | Gastric cancer | [ | |||
| TXNIP | Pancreatic cancer | [ | ||||
| PTX3 | Cervical cancer | [ | ||||
| hsa-mir-326 | DNA | hAT-Tip100 | Arthur1B | TWIST1 | Hepatocellular cancer | [ |
| hsa-mir-340-5p | DNA | TcMar-Mariner | MARNA | CDK4 | Non-small-cell lung cancer | [ |
| RhoA | Squamous Cell cancer | [ | ||||
| LGR5 | Breast cancer | [ | ||||
| hsa-mir-3664-3p | DNA | TcMar-Tigger | MER46C | UGT2B7 | Hepatocellular cancer | [ |
| hsa-mir-645 | DNA | hAT-Charlie | MER1B | SOX30 | Hepatocellular cancer | [ |
Differentially expressed miRNAs in the tissue of each of 9 types of cancer obtained from the TCGA database.
| Types of Cancer | Expression | miRNA | Subclass | Superfamily | Subfamily | log2FC | |
|---|---|---|---|---|---|---|---|
| BLCA | up | hsa-mir-584 | DNA | hAT-Blackjack | MER81 | 2.406 | 1.1 × 10−11 |
| down | hsa-mir-28 | LINE | L2 | L2c | −1.276 | 3.8 × 10−9 | |
| hsa-mir-582 | LINE | CR1 | L3b | −1.058 | 4.7 × 10−5 | ||
| hsa-mir-378a | SINE | MIR | MIRc | −1.426 | 7.2 × 10−5 | ||
| BRCA | up | hsa-mir-342 | SINE | tRNA-RTE | MamSINE1 | 2.392 | 5.2 × 10−18 |
| down | hsa-mir-378a | SINE | MIR | MIRc | −2.078 | 1.4 × 10−12 | |
| hsa-mir-335 | SINE | MIR | MIRb | −1.759 | 2.2 × 10−7 | ||
| CESC | up | hsa-mir-625 | LINE | L1 | L1MCa | 1.590 | 1.6 × 10−3 |
| hsa-mir-708 | LINE | L2 | L2c | 1.116 | 2.3 × 10−2 | ||
| down | hsa-mir-28 | LINE | L2 | L2c | −1.389 | 2.0 × 10−3 | |
| COAD | up | hsa-mir-151a | LINE | L2 | L2c | 1.010 | 6.6 × 10−8 |
| hsa-mir-584 | DNA | hAT-Blackjack | MER81 | 1.420 | 1.1 × 10−3 | ||
| down | hsa-mir-361 | DNA | hAT-Charlie | MER5A | −2.503 | 9.6 × 10−37 | |
| hsa-mir-378a | SINE | MIR | MIRc | −3.311 | 4.3 × 10−33 | ||
| hsa-mir-28 | LINE | L2 | L2c | −1.122 | 2.7 × 10−6 | ||
| hsa-mir-342 | SINE | tRNA-RTE | MamSINE1 | −1.454 | 1.1 × 10−4 | ||
| hsa-mir-625 | LINE | L1 | L1MCa | −1.484 | 1.9 × 10−4 | ||
| KIRC | up | hsa-mir-342 | SINE | tRNA-RTE | MamSINE1 | 1.085 | 5.8 × 10−8 |
| down | hsa-mir-891a | SINE | MIR | MIRc | −3.789 | 4.7 × 10−7 | |
| LIHC | up | hsa-mir-151a | LINE | L2 | L2c | 1.084 | 2.8 × 10−16 |
| LUAD | down | hsa-mir-378a | SINE | MIR | MIRc | −1.386 | 6.9 × 10−7 |
| PAAD | down | hsa-mir-342 | SINE | tRNA-RTE | MamSINE1 | −1.289 | 2.1 × 10−2 |
| STAD | down | hsa-mir-28 | LINE | L2 | L2c | −1.346 | 2.3 × 10−9 |
Figure 5Volcanoplot of differentially expressed miRNAs in the tissue of 9 types of cancer obtained from TCGA database. Only those MDTEs with the significant expression alteration that satisfy the condition (p < 0.05 and |log2FC| ≥ 1.0) are presented. Red dots represent significantly upregulated miRNAs, and greens for downregulated miRNAs.